The University of Oxford, a collegiate research university, is renowned for its academic excellence and global impact. It comprises a central university with academic departments, research centers, libraries, and museums, alongside 38 self-governing colleges and six permanent private halls. The university's success lies in its unique collegiate system, fostering interdisciplinary collaboration among leading academics and students from diverse backgrounds. Oxford University Innovation, established in 1987, is the university's technology transfer company. It manages the university's intellectual property portfolio, facilitating the commercialization of technologies through licensing, spin-out company formation, and material sales. Additionally, it manages Oxford University Consulting, providing clients access to the university's academic expertise. The university's strategic plan aims to lead the world in research and education, benefiting society on a national and global scale. Oxford University Innovation supports staff and students in applying their expertise and research for wider social and economic impact, sharing income with those involved according to the university's regulations. The university also operates advanced scholarly resources, enabling researchers and students to efficiently discover and engage with relevant academic material.
Mode Labs specializes in developing low-cost, portable, real-time chemical sensors for monitoring pollutants in natural waterways. Their micron-scale quantum technology enhances chemical absorption signals, delivering lab-grade sensitivity in a compact, easy-to-deploy, and highly scalable format.
Seloxium
Seed Round in 2025
Seloxium is a company focused on assisting mining, refining, and industrial sectors in achieving their environmental, social, and governance (ESG) objectives by transforming wastewater into profitable and sustainable resources. Utilizing advanced selective flocculation technology, Seloxium enables the extraction of valuable metals from wastewater and mine tailings, offering an innovative approach to metal recovery. This technology allows businesses to obtain high-purity metals from their waste streams while minimizing their carbon footprint and preventing harmful metals from entering the environment. By providing an effective solution for recycling and refining processes, Seloxium supports companies in enhancing their sustainability practices and improving their overall environmental impact.
OrganOx
Venture Round in 2025
OrganOx Limited, founded in 2008 and based in Oxford, United Kingdom, specializes in organ preservation and transplantation technology, particularly for liver transplants. The company has developed the Metra device, which employs normothermic preservation technology to store livers outside the body at normal body temperature. This innovative approach mimics the conditions of the human body by continuously perfusing the liver with oxygen-carrying red cells and nutrients, thereby preventing the decay of the organ before transplantation. The Metra device enables the liver to produce bile, metabolize glucose, and maintain a physiological pH level, ultimately enhancing the viability of the organ for transplant. OrganOx's research and development efforts are rooted in the work of Prof Peter Friend and Prof Constantin Coussios at the University of Oxford.
Diffblue
Series A in 2024
Diffblue Limited, based in Oxford, United Kingdom, specializes in artificial intelligence software that automates various coding tasks, primarily focusing on enhancing Java development through automated testing solutions. Founded in 2016 as a spin-out from the AI research group at Oxford, Diffblue's technology autonomously generates unit tests, which helps developers save time and ensure software robustness. The software not only creates fully formed tests guaranteed to compile and run, but also identifies and fixes bugs, refactors code, and maintains regression tests. By providing insights into test coverage, code testability, and complexity, Diffblue aims to transform the software development process, making it more efficient and less error-prone.
Fluorok
Seed Round in 2024
FluoRok is transforming the production of fluorochemicals with its innovative technology that prioritizes safety, sustainability, and cost-effectiveness. The company has developed a patented process that eliminates the use of hazardous hydrofluoric acid, providing a cleaner alternative for industries such as agrochemicals, pharmaceuticals, and materials. By offering a safer means of accessing fluorochemicals, FluoRok aims to support a more sustainable future while enabling businesses to meet their production needs without compromising safety or environmental standards.
Oria XR
Pre Seed Round in 2024
Oria XR is an innovative startup dedicated to revolutionizing medical training through the power of Virtual Reality (VR) and extended reality (XR) technologies. Our mission is to empower medical professionals and engineers with cutting-edge technology and unparalleled training experiences, ensuring they have the skills and confidence needed to excel in their fields. At Oria XR, we believe in setting the gold standard in medical training and support.
Oxford Endovascular
Series A in 2024
Oxford Endovascular is focused on developing an innovative medical device for the treatment of brain aneurysms. The company's technology employs a laser-cut metal alloy with shape-memory properties, which can be inserted into a patient's brain via a catheter. Once in place, the device expands into a tiny mesh tube, known as a flow diverter, that conforms to the natural shape of the blood vessel. This design effectively diverts blood flow away from the aneurysm, facilitating its healing and reducing the risk of rupture. By utilizing advanced origami engineering, Oxford Endovascular aims to enhance patient outcomes and improve survival rates for those affected by intracranial aneurysms.
Theolytics
Venture Round in 2024
Theolytics Limited is a clinical-stage biotechnology company founded in 2017 and based in Oxford, United Kingdom. The company specializes in developing oncolytic viral therapies to combat cancer, utilizing a phenotypic screening platform that facilitates the discovery and development of effective, targeted treatment candidates. These therapies are designed for intravenous delivery and tailored to specific patient populations, aiming to provide innovative care options. In addition to advancing its internal pipeline of programs that address both solid and liquid tumors, Theolytics is also focused on forming strategic partnerships to enhance and expedite its pipeline development.
CryoLogyx
Seed Round in 2024
CryoLogyx is an early-stage biotechnology company focused on advancing cell cryopreservation technology to enhance drug discovery processes. By employing innovative methods that utilize cryoprotectants, CryoLogyx transforms the freezing, storage, and transportation of cells. This proprietary technology ensures the delivery of viable, ready-to-use cells and cell therapies, allowing healthcare researchers to access these resources in the desired format. The company's approach aims to improve the efficiency and effectiveness of cell-based research in the fields of medicine discovery, diagnostics, and cell therapy.
NodeShift
Seed Round in 2024
NodeShift is a cloud service provider that offers a platform for businesses to build and host secure applications in a decentralized environment. The company focuses on delivering scalable and affordable cloud computing services, addressing the challenges associated with decentralization. By integrating various infrastructure and application services into a unified user interface, NodeShift simplifies the process for companies, allowing them to create and manage applications efficiently while maintaining security and cost-effectiveness.
Rhazes AI
Grant in 2023
Rhazes AI develops an AI-driven platform designed to enhance clinical productivity and reduce administrative burdens for healthcare professionals. The platform offers an intelligent assistant that improves diagnostic accuracy, transcribes notes, generates treatment plans, and aids in coding and billing. It also provides specialist-level support and documentation efficiency, allowing doctors to focus more on patient care and less on paperwork, thereby reducing burnout.
Navenio
Series A in 2023
Navenio Limited is a software technology company based in Oxford, United Kingdom, that specializes in location-based services for indoor environments. Founded in 2015, Navenio offers a mobile application solution that enhances indoor localization by enabling the tracking of individuals without the need for additional hardware, such as beacons or Wi-Fi. This innovative approach utilizes fingerprinting of the electromagnetic spectrum, sensor data, and indoor mapping to provide accurate location monitoring across various sectors, including retail, transportation, venues, and healthcare. Navenio's intelligent workforce solution significantly improves operational efficiency and workflow by automating processes based on real-world best practices.
Theolytics
Series A in 2023
Theolytics Limited is a clinical-stage biotechnology company founded in 2017 and based in Oxford, United Kingdom. The company specializes in developing oncolytic viral therapies to combat cancer, utilizing a phenotypic screening platform that facilitates the discovery and development of effective, targeted treatment candidates. These therapies are designed for intravenous delivery and tailored to specific patient populations, aiming to provide innovative care options. In addition to advancing its internal pipeline of programs that address both solid and liquid tumors, Theolytics is also focused on forming strategic partnerships to enhance and expedite its pipeline development.
OxCCU
Series A in 2023
OxCCU specializes in renewable energy technology aimed at fostering a circular economy for fuels, chemicals, and plastics. The company’s innovative approach utilizes carbon dioxide extracted from the atmosphere, hydrogen sourced from water, and renewable electricity to produce sustainable fuels, chemicals, and biodegradable plastics. By doing so, OxCCU enables clients to adopt more environmentally friendly products, contributing to a more sustainable future.
Caristo Diagnostics
Series A in 2023
Caristo Diagnostics Limited, founded in 2018 as a spin-out from the University of Oxford, specializes in artificial intelligence-based software for diagnosing cardiovascular conditions. The company has developed the CaRi-Heart technology, an advanced imaging platform that enhances the prediction and diagnosis of coronary artery disease, heart attacks, strokes, and diabetes. Utilizing Cardiac Computed Tomography Angiography (CCTA), the platform measures the Fat Attenuation Index (FAI), a patented biomarker for coronary inflammation. The CaRi-Heart Report provides clinicians with critical insights, including patient-specific FAI, an assessment of the absolute 8-year risk of a fatal heart attack, and detailed characterization of coronary plaque. The technology is CE Mark certified and has received recognition in prestigious medical journals, showcasing its efficacy in predicting heart attacks. Caristo has secured over £23 million in venture capital and has been supported by various UK government grants for its innovative care pathways. With its unique combination of clinical insights and advanced technology, Caristo aims to transform cardiac care globally by improving risk prediction and prevention strategies.
OMass Therapeutics
Series B in 2022
OMass Therapeutics Limited is a biotechnology company based in Oxford, United Kingdom, established in 2016. The company specializes in drug discovery, utilizing structural mass spectrometry technology to develop innovative therapeutics aimed at difficult disease targets. Its platform allows clients to access native mass spectrometry without the need for sophisticated instrumentation or in-house expertise. This capability enables the study of complex protein assemblies and their interactions with other biological molecules, facilitating the development of drugs and biotherapeutics. OMass Therapeutics aims to provide a dynamic and collaborative environment for biotechnology and pharmaceutical clients to address challenging drug targets effectively.
Brainomix
Series B in 2021
Brainomix Limited, established in 2010 as a spin-out from the University of Oxford, develops advanced imaging biomarkers and software solutions aimed at enhancing clinical decision-making for neurological and cerebrovascular disorders. The company's flagship product, e-Stroke, employs state-of-the-art artificial intelligence algorithms to automate the interpretation of brain scans, specifically for acute ischemic stroke patients. This tool assists physicians in identifying and quantifying early stroke damage, thereby facilitating timely and informed treatment decisions. In addition to e-Stroke, Brainomix offers other software products such as e-ASPECTS, which automates the Alberta Stroke Program Early CT Score, and e-CTA, which standardizes the assessment of large vessel occlusion locations. These innovative solutions address the critical need for rapid and consistent evaluations of brain CT scans, ultimately optimizing patient outcomes and ensuring that stroke patients receive appropriate care in a timely manner. The company is headquartered in Oxford, United Kingdom.
Navenio
Venture Round in 2021
Navenio Limited is a software technology company based in Oxford, United Kingdom, that specializes in location-based services for indoor environments. Founded in 2015, Navenio offers a mobile application solution that enhances indoor localization by enabling the tracking of individuals without the need for additional hardware, such as beacons or Wi-Fi. This innovative approach utilizes fingerprinting of the electromagnetic spectrum, sensor data, and indoor mapping to provide accurate location monitoring across various sectors, including retail, transportation, venues, and healthcare. Navenio's intelligent workforce solution significantly improves operational efficiency and workflow by automating processes based on real-world best practices.
Mach42
Series A in 2021
Machine Discovery is a spin-out from the University of Oxford focused on commercializing advanced machine learning technology. The company has developed a simulation management platform that utilizes proprietary neural network technology to enhance the efficiency of compute-intensive tasks. This platform enables clients to conduct simulations with minimal data input while achieving a high level of accuracy, specifically 99.9% fidelity. By accelerating costly calculations, Machine Discovery provides valuable statistical insights that aid clients in speeding up their innovation processes, thus addressing critical demands in various sectors.
PepGen
Series A in 2020
PepGen is a clinical-stage biotechnology company based in Oxford, United Kingdom, focused on advancing nucleic acid therapeutics, particularly antisense oligonucleotides. Founded in 2018, the company aims to enhance the delivery and efficacy of these therapies through its proprietary Enhanced Delivery Oligonucleotide (EDO) platform. This innovative platform utilizes engineered peptides designed to improve tissue penetration, cellular uptake, and nuclear delivery of oligonucleotides. PepGen's technology has shown promise in preclinical studies, demonstrating the ability to transport therapeutics effectively into various target tissues, including smooth, skeletal, and cardiac muscle, as well as the central nervous system. The company's mission is to unlock the full potential of nucleic acid therapeutics to transform the treatment landscape for severe neuromuscular and neurological diseases.
Refeyn
Series A in 2020
Refeyn Ltd, founded in 2018 and based in Oxford, United Kingdom, specializes in mass photometry technology for the analysis of biomolecules. The company's flagship product, Refeyn One, employs single molecule light scattering to detect, image, and accurately determine the mass of biomolecules in solution. This innovative optical technology allows researchers to measure the mass of individual molecules in their native state without the necessity for labels, providing both quality-control instruments and advanced research tools. Refeyn's offerings enable scientists to conduct mass measurements across a range of biologically relevant concentrations, enhancing the capabilities of biomolecular analysis.
Oxford Flow
Venture Round in 2020
Oxford Flow Ltd. is a company that designs, manufactures, and supplies pressure control equipment, including gas regulators, water pressure reducing valves (PRVs), silencers, and pilots. Established in 2015 and based in Oxford, United Kingdom, the company serves a variety of industries such as water, gas, marine, oil and gas, process, power, and building services. Oxford Flow's products are engineered to simplify systems and enhance reliability while meeting rigorous standards for water quality and leakage control. The company focuses on delivering practical solutions that improve operational efficiency and reduce environmental impact, backed by extensive testing and customer feedback. By combining academic expertise with industry knowledge, Oxford Flow aims to provide innovative and efficient pressure control solutions that help customers save costs without compromising performance.
Navenio
Series A in 2020
Navenio Limited is a software technology company based in Oxford, United Kingdom, that specializes in location-based services for indoor environments. Founded in 2015, Navenio offers a mobile application solution that enhances indoor localization by enabling the tracking of individuals without the need for additional hardware, such as beacons or Wi-Fi. This innovative approach utilizes fingerprinting of the electromagnetic spectrum, sensor data, and indoor mapping to provide accurate location monitoring across various sectors, including retail, transportation, venues, and healthcare. Navenio's intelligent workforce solution significantly improves operational efficiency and workflow by automating processes based on real-world best practices.
Perspectum
Venture Round in 2020
Perspectum is a global medical technology company that focuses on improving care for patients with liver disease, diabetes, and cancer. By utilizing advanced imaging and genetics, the company emphasizes precision medicine to enhance early detection, diagnosis, and targeted treatment of complex health issues. Perspectum's diverse team, which includes physicians, biomedical scientists, engineers, and technologists, works collaboratively to develop innovative digital technologies. Their aim is to empower both patients and clinicians by providing quantitative health assessments, enabling more effective management of metabolic diseases and multi-organ pathology.
Oxford VR
Series A in 2020
Oxford VR Limited specializes in developing cognitive treatments for various clinical conditions using virtual reality technology. Founded in 2016 and based in Oxford, United Kingdom, the company leverages extensive research from Professor Daniel Freeman to create automated therapies delivered by a virtual coach. These innovative treatments address issues such as fear of heights, psychosis, and social anxiety. By utilizing immersive VR experiences, Oxford VR aims to provide faster, more effective, and cost-efficient psychological interventions compared to traditional methods. The company's focus is on delivering clinically validated and user-centered solutions that enhance access to mental health care, benefiting patients, healthcare professionals, and the broader health system.
Zegami
Series B in 2019
Zegami Limited is a company that specializes in visual data exploration tools designed for the analysis of large collections of images, particularly in scientific and medical contexts. Founded in 2015 and headquartered in Oxford, United Kingdom, Zegami transforms visual data into actionable information by integrating media, data, and artificial intelligence. Its platform supports users in searching, sorting, filtering, and grouping data, which facilitates the identification of patterns, correlations, and anomalies. The solution caters to a variety of sectors, including heating, ventilation, and air conditioning (HVAC) management, microscopy, genomics, and cultural heritage organizations such as galleries and museums. Additionally, Zegami offers a plugin API that enables developers to create custom visualizations, enhancing the platform's versatility and applicability across different fields.
Zegami
Series B in 2019
Zegami Limited is a company that specializes in visual data exploration tools designed for the analysis of large collections of images, particularly in scientific and medical contexts. Founded in 2015 and headquartered in Oxford, United Kingdom, Zegami transforms visual data into actionable information by integrating media, data, and artificial intelligence. Its platform supports users in searching, sorting, filtering, and grouping data, which facilitates the identification of patterns, correlations, and anomalies. The solution caters to a variety of sectors, including heating, ventilation, and air conditioning (HVAC) management, microscopy, genomics, and cultural heritage organizations such as galleries and museums. Additionally, Zegami offers a plugin API that enables developers to create custom visualizations, enhancing the platform's versatility and applicability across different fields.
Oxford Semantic Technologies
Series A in 2019
Oxford Semantic Technologies is a company focused on developing RDFox, a high-performance knowledge graph and semantic reasoning engine designed to leverage modern multi-core architecture. Founded in 2017 as a spin-out from the University of Oxford, the company aims to translate advanced research in semantic web technologies into practical industrial applications. The RDFox engine, which started development in 2011, employs patented computing techniques that allow for the rapid processing of complex queries, significantly reducing the need for IT expertise. This capability enables domain experts to formulate their own queries, streamline development cycles for data analysis, and validate results through detailed explanations of how answers are derived from the underlying data. Oxford Semantic Technologies has positioned itself as a key player in unlocking innovative enterprise applications for its clients.
Oxford VR
Venture Round in 2018
Oxford VR Limited specializes in developing cognitive treatments for various clinical conditions using virtual reality technology. Founded in 2016 and based in Oxford, United Kingdom, the company leverages extensive research from Professor Daniel Freeman to create automated therapies delivered by a virtual coach. These innovative treatments address issues such as fear of heights, psychosis, and social anxiety. By utilizing immersive VR experiences, Oxford VR aims to provide faster, more effective, and cost-efficient psychological interventions compared to traditional methods. The company's focus is on delivering clinically validated and user-centered solutions that enhance access to mental health care, benefiting patients, healthcare professionals, and the broader health system.
Evox Therapeutics
Series B in 2018
Evox Therapeutics is a biotechnology company based in Oxford, United Kingdom, founded in 2016. The company specializes in developing exosome-based therapeutics aimed at treating rare and severe diseases. By harnessing and engineering the natural delivery capabilities of extracellular vesicles, known as exosomes, Evox focuses on creating innovative drug delivery systems that utilize nucleic acids and proteins. This technology allows for targeted delivery to specific organs, including the brain and central nervous system, addressing limitations often encountered with traditional therapies. Evox's proprietary methods for modifying exosomes enhance their ability to transport therapeutic agents effectively, thereby improving treatment options for patients with limited alternatives. The company is supported by a strong intellectual property portfolio and investments from leading life sciences venture capital groups, positioning it as a leader in the emerging field of exosome-based therapeutics.
Refeyn
Venture Round in 2018
Refeyn Ltd, founded in 2018 and based in Oxford, United Kingdom, specializes in mass photometry technology for the analysis of biomolecules. The company's flagship product, Refeyn One, employs single molecule light scattering to detect, image, and accurately determine the mass of biomolecules in solution. This innovative optical technology allows researchers to measure the mass of individual molecules in their native state without the necessity for labels, providing both quality-control instruments and advanced research tools. Refeyn's offerings enable scientists to conduct mass measurements across a range of biologically relevant concentrations, enhancing the capabilities of biomolecular analysis.
BibliU
Seed Round in 2018
BibliU Ltd is a software platform developed to provide online access to textbooks and educational materials, catering primarily to colleges and universities. Founded in 2014 and headquartered in London, with an additional office in New York, BibliU offers a comprehensive digital content management solution that allows students to access textbooks and supplementary courseware from various devices anytime and anywhere. The platform boasts partnerships with thousands of publishers and open educational resource providers, making millions of digital resources available. Key features include instant access to course content, a discovery search tool, offline support, and analytics, along with synchronized highlights and comments to enhance the learning experience. Overall, BibliU aims to blend academic accessibility with affordability and automation in education.
Orbit Discovery
Series A in 2018
Orbit Discovery Ltd. is a biotechnology company specializing in peptide display technology to discover peptide drugs for chronic diseases. Established in 2015 and based in Oxford, United Kingdom, the company utilizes an innovative in vitro bead display platform that links randomized peptide sequences to their encoding DNA. This technology enables high-throughput screening of peptides, facilitating the identification and optimization of potential drug candidates. By combining the specificity and efficacy of large biologic molecules with the advantages of small molecules, such as lower manufacturing costs and simpler delivery methods, Orbit Discovery aims to address a wide range of chronic diseases affecting large patient populations. The company's focus is on both internal drug discovery programs and collaborative research efforts, streamlining the discovery process and accelerating the development of new peptide therapeutics.
Oxford Flow
Venture Round in 2018
Oxford Flow Ltd. is a company that designs, manufactures, and supplies pressure control equipment, including gas regulators, water pressure reducing valves (PRVs), silencers, and pilots. Established in 2015 and based in Oxford, United Kingdom, the company serves a variety of industries such as water, gas, marine, oil and gas, process, power, and building services. Oxford Flow's products are engineered to simplify systems and enhance reliability while meeting rigorous standards for water quality and leakage control. The company focuses on delivering practical solutions that improve operational efficiency and reduce environmental impact, backed by extensive testing and customer feedback. By combining academic expertise with industry knowledge, Oxford Flow aims to provide innovative and efficient pressure control solutions that help customers save costs without compromising performance.
Brainomix
Venture Round in 2018
Brainomix Limited, established in 2010 as a spin-out from the University of Oxford, develops advanced imaging biomarkers and software solutions aimed at enhancing clinical decision-making for neurological and cerebrovascular disorders. The company's flagship product, e-Stroke, employs state-of-the-art artificial intelligence algorithms to automate the interpretation of brain scans, specifically for acute ischemic stroke patients. This tool assists physicians in identifying and quantifying early stroke damage, thereby facilitating timely and informed treatment decisions. In addition to e-Stroke, Brainomix offers other software products such as e-ASPECTS, which automates the Alberta Stroke Program Early CT Score, and e-CTA, which standardizes the assessment of large vessel occlusion locations. These innovative solutions address the critical need for rapid and consistent evaluations of brain CT scans, ultimately optimizing patient outcomes and ensuring that stroke patients receive appropriate care in a timely manner. The company is headquartered in Oxford, United Kingdom.
Navenio
Seed Round in 2017
Navenio Limited is a software technology company based in Oxford, United Kingdom, that specializes in location-based services for indoor environments. Founded in 2015, Navenio offers a mobile application solution that enhances indoor localization by enabling the tracking of individuals without the need for additional hardware, such as beacons or Wi-Fi. This innovative approach utilizes fingerprinting of the electromagnetic spectrum, sensor data, and indoor mapping to provide accurate location monitoring across various sectors, including retail, transportation, venues, and healthcare. Navenio's intelligent workforce solution significantly improves operational efficiency and workflow by automating processes based on real-world best practices.
Oxford Biotrans
Series B in 2017
Oxford Biotrans Limited is a company based in Abingdon, United Kingdom, that focuses on the development and commercialization of high-value chemical compounds through enzyme technology. Established in 2013, it leverages patented cytochrome P450 enzyme technology to create products such as Nootkatone, a naturally derived flavor and fragrance from Valencene, a citrus extract. The company aims to introduce innovative enzymatic routes for producing specialty chemicals, with initial offerings centered on flavors and fragrances. Additionally, the technology has broader applications in the production of pheromones, pharmaceuticals, and other specialty chemicals. With over 15 years of research backing its initiatives, Oxford Biotrans is committed to providing environmentally friendly ingredients that minimize chemical waste and energy consumption.
Zegami
Series A in 2017
Zegami Limited is a company that specializes in visual data exploration tools designed for the analysis of large collections of images, particularly in scientific and medical contexts. Founded in 2015 and headquartered in Oxford, United Kingdom, Zegami transforms visual data into actionable information by integrating media, data, and artificial intelligence. Its platform supports users in searching, sorting, filtering, and grouping data, which facilitates the identification of patterns, correlations, and anomalies. The solution caters to a variety of sectors, including heating, ventilation, and air conditioning (HVAC) management, microscopy, genomics, and cultural heritage organizations such as galleries and museums. Additionally, Zegami offers a plugin API that enables developers to create custom visualizations, enhancing the platform's versatility and applicability across different fields.
Diffblue
Series A in 2017
Diffblue Limited, based in Oxford, United Kingdom, specializes in artificial intelligence software that automates various coding tasks, primarily focusing on enhancing Java development through automated testing solutions. Founded in 2016 as a spin-out from the AI research group at Oxford, Diffblue's technology autonomously generates unit tests, which helps developers save time and ensure software robustness. The software not only creates fully formed tests guaranteed to compile and run, but also identifies and fixes bugs, refactors code, and maintains regression tests. By providing insights into test coverage, code testability, and complexity, Diffblue aims to transform the software development process, making it more efficient and less error-prone.
Scenic Biotech
Series A in 2017
Scenic Biotech, established in 2017 and headquartered in Amsterdam, Netherlands, specializes in developing genomics and immunotherapy technologies to combat cancer and rare genetic diseases. The company's core focus is to identify and harness disease-suppressing genes, which can act as an "off-switch" for genetic disorders, thereby creating novel drug targets and therapies. By leveraging genomics, Scenic Biotech aims to revolutionize the treatment of severe diseases by tackling them at their genetic source.
Bodle Technologies
Seed Round in 2017
Bodle Technologies, established in 2015 and based in Begbroke, UK, specializes in advanced optoelectronic solutions. The company's core product is its proprietary SRD® technology, the world's first solid-state reflective display, which uses phase-change materials. This innovative display offers ultra-high resolution, vivid color, and video capability, consuming zero energy for static image storage. Bodle's reflective displays are designed for wearables, near-eye, and projection-based displays, providing a more natural viewing experience, particularly in outdoor or sunlight conditions. Additionally, the company develops smart windows and security coatings that employ color-changing techniques, enhancing the durability and security of currencies, ID cards, and official documentation.
Fuel3D
Venture Round in 2017
Fuel3D is a company that specializes in advanced 3D scanning technology, offering an affordable handheld scanner designed for high-quality shape and color capture across various creative applications. The scanner utilizes a unique combination of pre-calibrated stereo cameras and photometric imaging to produce detailed 3D images quickly, making it accessible to independent game developers, designers, and artists. Originally developed for the medical imaging sector at Oxford University by a team of engineers and scientists, Fuel3D's technology has been adapted for broader markets, aiming to democratize point-and-shoot 3D imaging. The company, now led by CEO Stuart Mead, focuses on providing rapid and accurate analysis of organic subjects, serving clients in fields ranging from art and animation to gaming and retail.
Fungry
Venture Round in 2017
Fungry is an online food application dedicated to enhancing the quality of takeaway food in Oxford by connecting customers with local independent restaurants. The platform simplifies the process of discovering exceptional cuisine by featuring a curated selection of dishes crafted by local chefs. Fungry emphasizes the importance of supporting local businesses while ensuring that customers enjoy a diverse range of high-quality food options. By streamlining the search for great local dining, Fungry aims to provide a convenient and satisfying takeaway experience for its users.
Covatic
Series A in 2017
Covatic Ltd, established in 2016 and headquartered in Birmingham, United Kingdom, specializes in broadcast personalization software. The company's innovative platform employs mobile-based algorithms to enhance user experience by delivering personalized content without compromising personal data. By identifying optimal engagement moments and methods for individuals, Covatic enables clients to effectively connect with their target audiences. This approach allows for the collection and personalization of insights, ultimately improving the way applications serve their users. With an emphasis on problem-solving, Covatic continues to develop solutions that enhance app functionality and user interaction.
Cycle.land
Equity Crowdfunding in 2016
Cycle.land Limited operates an online bicycle sharing platform based in Oxford, United Kingdom, with additional offices in Cambridge and Edinburgh. Founded in 2016, the company connects bike owners with individuals seeking bicycles, facilitating rentals during times when the owners are not using their bikes. The platform serves colleges, businesses, and institutions, allowing users to find, share, and book bicycles from local cyclists and vendors. This service promotes a vibrant community of cycling enthusiasts, fostering connections among students, residents, and visitors. By enabling easy access to bicycles, Cycle.land not only supports sustainable transportation but also encourages social interaction within the cycling community.
Redacto
Venture Round in 2016
Redacto represents a totally new approach to online language learning. Using authentic recordings of people from different walks of life, as well as news broadcasts and vox pops, Redacto provides English language learners of all levels with intensive and relevant listening practice. Users are supported by hints, score feedback, variable audio speed and Google’s speech to text technology. Students can invite a friend to compete against online. Both users can collaborate in real time as they see each other’s correctly guessed words populate their screens, along with scores and feedback. Learning is consolidated by post listening vocabulary exercises.
Cycle.land
Venture Round in 2016
Cycle.land Limited operates an online bicycle sharing platform based in Oxford, United Kingdom, with additional offices in Cambridge and Edinburgh. Founded in 2016, the company connects bike owners with individuals seeking bicycles, facilitating rentals during times when the owners are not using their bikes. The platform serves colleges, businesses, and institutions, allowing users to find, share, and book bicycles from local cyclists and vendors. This service promotes a vibrant community of cycling enthusiasts, fostering connections among students, residents, and visitors. By enabling easy access to bicycles, Cycle.land not only supports sustainable transportation but also encourages social interaction within the cycling community.
Bodle Technologies
Seed Round in 2015
Bodle Technologies, established in 2015 and based in Begbroke, UK, specializes in advanced optoelectronic solutions. The company's core product is its proprietary SRD® technology, the world's first solid-state reflective display, which uses phase-change materials. This innovative display offers ultra-high resolution, vivid color, and video capability, consuming zero energy for static image storage. Bodle's reflective displays are designed for wearables, near-eye, and projection-based displays, providing a more natural viewing experience, particularly in outdoor or sunlight conditions. Additionally, the company develops smart windows and security coatings that employ color-changing techniques, enhancing the durability and security of currencies, ID cards, and official documentation.
Xerion Healthcare
Series A in 2015
Xerion Healthcare Limited, founded in 2015 and based in Thame, United Kingdom, specializes in developing and commercializing innovative nanoparticle treatments aimed at improving cancer care. The company focuses on utilizing titanium dioxide nanoparticles, which are injected into tumors prior to standard radiotherapy. This method enhances the effectiveness of radiotherapy by amplifying the dose of free radicals generated by X-rays, allowing for more effective treatment of dense tumors. Xerion Healthcare is currently advancing its technology for head, neck, and pancreatic cancers, with the goal of improving patient outcomes while minimizing side effects associated with conventional cancer treatments.
Gyana
Seed Round in 2015
Gyana is an innovative online platform that simplifies data analysis for businesses by providing a no-code, visual interface for creating reports and dashboards. The platform enables users to effortlessly collect and interpret data from various digital tools or spreadsheets, automatically refreshing to ensure access to the latest insights. Gyana's preset visualization and insight models allow users to extract meaningful value from their data without requiring programming skills. It supports a streamlined data journey, making it possible to generate comprehensive performance reports in minutes rather than days. Users can customize their reports and dashboards, share them easily, and export them in PDF format. Upcoming features include additional data connectors, collaboration tools, and report automation, enhancing the platform's functionality. By leveraging big data and artificial intelligence, Gyana empowers B2C businesses to gain critical insights that drive decision-making and improve overall performance.
Wrapidity
Convertible Note in 2015
Wrapidity Limited is a London-based company that specializes in web data extraction, transforming unstructured web content into structured data formats. Established in 2015 and operating as a subsidiary of Meltwater News US Inc., Wrapidity employs artificial intelligence to automate the data extraction process. This technology eliminates the need for manual web scraping, which can be time-consuming and costly, by allowing users to provide a small sample of the desired data. The AI then determines the appropriate websites to crawl, how to interact with their content, and the best methods for continuous data extraction. This innovation benefits a range of users, including businesses, policymakers, and scientists, by enabling them to efficiently collect and analyze relevant data from the web without the overhead of traditional engineering resources.
Total Mama
Venture Round in 2014
Total Mama is a digital health company focused on supporting women throughout various stages of motherhood, including pre-pregnancy, pregnancy, and postpartum. The company utilizes AI-based technology to deliver personalized, evidence-based health information tailored to individual health profiles and demographic data. By aligning this information with national clinical guidelines and other reputable sources, Total Mama aims to provide women with reliable maternal and reproductive health resources. The platform facilitates access to valuable guidance and insights from third-party content providers, empowering women to make informed decisions regarding their health and well-being during critical periods of their lives.
Genomics
Series A in 2014
Genomics PLC, established in 2014 and headquartered in Oxford, UK, specializes in developing algorithms and software solutions that harness the power of genomics. The company focuses on cancer, microbes, and rare diseases, offering solutions that transform healthcare provisions for governments and providers, de-risk drug development for pharmaceutical clients, enhance diagnoses and treatment options for clinicians, and ensure accurate result processing for research labs and genome analysts. By applying advanced analytics to massive genomic and phenotypic datasets, Genomics PLC aims to lead the genomic transformation of healthcare, revealing the human wiring diagram and setting standards for genomic data utilization.
Oxa
Seed Round in 2014
Oxa is a developer of autonomous vehicle software that focuses on creating AI-based platforms for the operation and scaling of fleets of autonomous vehicles. The company's technology combines laser vision and radar for effective localization, allowing autonomous systems to understand their surroundings and navigate safely in complex environments. Oxa's software is designed to operate with low compute power requirements, making it accessible for various business applications. By providing solutions that enhance vehicle positioning and movement prediction, Oxa enables clients to implement and accelerate the deployment of autonomous vehicles in a range of settings.
Oxford BioChronometrics
Venture Round in 2014
Oxford BioChronometrics, founded in 2014, specializes in developing cyber security software aimed at combating digital fraud. Originating from technology at the Oxford University Innovation center, the company offers a suite of products designed to enhance the integrity of online advertising and secure web interactions. Their Digital Media Solutions quantify fraud, particularly from non-human sources, enabling advertisers to verify and optimize their traffic sources. The SecureAd Suite provides measurable insights into ad performance across various platforms, ensuring that advertisers only pay for legitimate engagement. Additionally, their Cyber Solutions focus on preventing fraud before it occurs, using continuous credential validation to ensure only human users access services. Key products include Secure Form, a tool to mitigate spam, SecureLeads for verifying genuine form submissions, and Secure Checkout, which prevents fraudulent credit card entries. The company has gained recognition for its innovative approach, including winning the NATO 2017 Defense Innovation Challenge, and continues to expand its offerings with upcoming products like their Fake News solution.
Adaptimmune Therapeutics
Series A in 2014
Adaptimmune Therapeutics, established in 2008, is a UK-based clinical-stage biopharmaceutical company specializing in novel cell therapies for solid tumor patients. Its core technology, the Specific Peptide Enhanced Affinity Receptor (SPEAR) T-cell platform, enables the identification of cancer targets and the development of affinity-enhanced T-cell receptors. Adaptimmune's pipeline includes several SPEAR T-cell therapies in phase I clinical trials, targeting various solid tumors such as urothelial, melanoma, and non-small cell lung cancer. The company has strategic collaborations with GSK, Noile-Immune Biotech, and Universal Cells, Inc. to advance its T-cell therapies.
Oxitec
Venture Round in 2014
Oxitec Limited is a biotechnology company based in Oxford, United Kingdom, focused on developing innovative solutions for controlling insect pests that transmit diseases and damage crops. Founded in 2002, the company employs proprietary genetic technology to enhance the effectiveness and safety of pest control methods, particularly the Sterile Insect Technique (SIT). Oxitec's products include various genetically modified strains of insects, such as the Aedes aegypti mosquito and the Diamondback moth, designed to reduce populations of disease-carrying and crop-damaging species. These strains are engineered for specific environments in Asia and Latin America and include features like female lethality and fluorescent markers for easy identification. With a mosquito production facility in Brazil, Oxitec aims to provide sustainable, non-toxic alternatives for pest management, thereby contributing to global health and agricultural productivity while minimizing environmental impact.
OxSyBio
Seed Round in 2014
OxSyBio Ltd. specializes in developing advanced 3D printing techniques to create tissue-like and functional tissues for medical research and clinical applications. The company focuses on producing innovative materials made up of three-dimensional networks of lipid monolayer aqueous droplets. These materials can conduct electrical signals along designated pathways and have the ability to self-fold into complex geometries. This technology has potential applications in regenerative medicine, including organ repair and replacement, aiming to enhance precision medicine. Founded in 2014 and based in London, OxSyBio draws upon cutting-edge research from Professor Hagan Bayley's group at the University of Oxford, known for its expertise in chemical and synthetic biology.
Designer Carbon Materials
Seed Round in 2014
Designer Carbon Materials Ltd specializes in the development of advanced nanomaterials, focusing on endohedral metallofullerenes for various applications such as energy harvesting, bio-sensing, and quantum nanoelectronics. The company emerged as a spin-out from the University of Oxford, building on over 12 years of research led by Dr. Kyriakos Porfyrakis and his team. They have successfully synthesized and chemically functionalized endohedral fullerenes, creating materials with tailored electronic properties. This innovative approach allows clients to utilize a range of nanostructures, including nanotubes and their derivatives, in both scientific and industrial applications.
Singular Intelligence
Venture Round in 2014
Singular Intelligence Limited specializes in developing an artificial intelligence platform for brands and retailers, focusing on the consumer packaged goods, food and drink, beauty, and home care sectors. The platform enhances commercial decision-making by automating processes related to pricing, promotions, marketing mix modeling, and supply planning, while also facilitating retail, e-commerce, and direct-to-consumer automation. Founded in 2013 and headquartered in London, the company leverages advanced analytics, AI, and big data to provide accurate insights that support businesses in real-time decision-making. Singular Intelligence emphasizes the importance of integrating various market factors to optimize marketing strategies and improve performance indicators. The company's innovative offerings include SiDAX™, a dynamic insight solution that utilizes visual analytics and smart data to empower organizations to make timely decisions based on a diverse array of data.
Genomics
Seed Round in 2014
Genomics PLC, established in 2014 and headquartered in Oxford, UK, specializes in developing algorithms and software solutions that harness the power of genomics. The company focuses on cancer, microbes, and rare diseases, offering solutions that transform healthcare provisions for governments and providers, de-risk drug development for pharmaceutical clients, enhance diagnoses and treatment options for clinicians, and ensure accurate result processing for research labs and genome analysts. By applying advanced analytics to massive genomic and phenotypic datasets, Genomics PLC aims to lead the genomic transformation of healthcare, revealing the human wiring diagram and setting standards for genomic data utilization.
OxCEPT
Seed Round in 2014
OxCEPT specializes in cybersecurity by developing a military-grade authentication application that enhances data privacy through secure real-time communication. The company's proprietary technology, protected by patents, includes a cross-platform mobile application and a back-end server system designed to ensure secure data transmission across all devices. By providing robust authentication and encryption products, OxCEPT enables organizations, including those in the military sector, to establish secure communication channels, thereby safeguarding sensitive information and communications in critical environments.
Chronos Therapeutics
Venture Round in 2013
Chronos Therapeutics is a drug development company dedicated to creating treatments for age-related diseases, particularly those affecting the nervous system. The company engages in research and development aimed at repositioning existing drugs, as well as discovering and developing novel proprietary drug candidates. By focusing on these areas, Chronos Therapeutics aims to provide healthcare professionals with advanced treatment options for patients suffering from nervous system disorders, ultimately enhancing recovery outcomes.
Oxford MEStar
Seed Round in 2013
Oxford MEStar is a company focused on translational and regenerative medicine, dedicated to developing innovative technologies and providing bioengineering solutions. It specializes in creating products and services for the translational and regenerative medicine industry, particularly in the areas of stem cell processing, engineered tissue manufacturing, and cellular bioproducts. The company possesses significant technical expertise in bioprocessing, bioengineering, and bio-manufacturing, allowing it to offer advanced solutions such as 3D bioprinting and in-vitro diagnostic development. Oxford MEStar also facilitates technology transfer between the UK and China, enhancing collaboration in the field of regenerative medicine.
VDabble
Venture Round in 2013
VDabble is a provider of subscription-based fun boxes designed to engage and inspire children aged 3 to 7 years through creative learning activities. Their product, the DabbleBox, is a monthly delivery that includes a variety of themed supplies such as learning puzzles, pictorial charts, craft books, and other tools aimed at fostering creativity and exploration. By offering these curated experiences directly to homes, VDabble enables young minds to discover new lessons and enhance their creativity in an enjoyable and interactive manner.
Perspectum
Seed Round in 2013
Perspectum is a global medical technology company that focuses on improving care for patients with liver disease, diabetes, and cancer. By utilizing advanced imaging and genetics, the company emphasizes precision medicine to enhance early detection, diagnosis, and targeted treatment of complex health issues. Perspectum's diverse team, which includes physicians, biomedical scientists, engineers, and technologists, works collaboratively to develop innovative digital technologies. Their aim is to empower both patients and clinicians by providing quantitative health assessments, enabling more effective management of metabolic diseases and multi-organ pathology.
Starticles
Venture Round in 2013
Starticles is an online platform that allows individuals to showcase their knowledge and ideas by sharing content such as research and insights. Users can present their work to the Starticles community, which provides ratings and feedback on the submissions. This interactive process enables users to earn recognition and points based on the quality of their contributions. As users gain recognition for their content, they enhance their profiles, thereby increasing their career opportunities. The platform focuses on valuing the quality of ideas over traditional qualifications, fostering a community that encourages knowledge sharing and expertise.
Oxpert
Venture Round in 2013
Oxpert specializes in providing online business software designed to assist micro businesses, particularly tradespeople like gas engineers and electricians, in enhancing their web presence and managing their operations. The company offers tools that enable these small enterprises to grow and effectively compete against larger competitors by streamlining brand management and operational processes. Through its services, Oxpert aims to empower tradespeople to establish a stronger foothold in the market and improve their overall business performance.
OxLegal
Venture Round in 2013
OxLegal is a software development company that focuses on providing technological solutions for legal professionals and corporate users. The company's tools include semantic tagging and natural language aids designed to enhance contract drafting and due diligence processes. By streamlining workflow and improving productivity in commercial transactions, OxLegal enables law firms to complete tasks more efficiently, thereby reducing costs associated with IT implementation and staff training. This allows lawyers to concentrate on more strategic work while also mitigating risks to protect their reputations.
TipTapped
Venture Round in 2013
TipTapped is a sports data provider. We analyse social media to find out what people are saying about upcoming sports games. TipTapped aggregate the data to show outcome forecasts for upcoming games, along with the complete prediction histories for each individual.We then share this data with sports fans, sports media and other sports companies.
Edspire
Venture Round in 2013
Edspire is an online learning platform that serves as a search engine for educational resources, utilizing advanced algorithms to classify a wide range of content including MOOCs, videos, OpenCourseWare, tutorials, and screencasts. In response to the rapid expansion of online educational resources, Edspire aims to facilitate users in navigating the diverse array of learning materials available, which disrupts traditional educational methods. The platform recognizes the increasing trend of individuals seeking customized learning experiences through various providers, rather than relying solely on conventional institutions. By providing a context for these diverse resources, Edspire helps users identify materials that best support their formal studies and professional development. The company is incubated by the Isis software incubator, part of Isis Innovation at the University of Oxford.
Oxford Vacmedix
Seed Round in 2013
Oxford Vacmedix was established in 2012 as a spinout from Oxford University. Its aim is to develop therapeutic agents for the treatment of cancer based on the invention of Dr Shisong Jiang - Recombinant Overlapping Peptides (ROP). These agents are an exciting new way to deliver immunotherapy which is now a major focus in the treatment of cancer, making it easier to deliver, more effective and much more economical. Immunotherapy is effective by activating the immune system to attack tumours directly thus reducing the need for invasive treatments such as chemo and radiotherapy.
goKomplain
Venture Round in 2012
goKomplain lets you to voice your discontent and allows the public to offer solutions.
SmartEatOut
Venture Round in 2012
SmartEatOut is a group dining solution bringing together people and restaurants. By signing up for free people can join Smart-groups and meet others around the table or simply book a table for a private celebration with their friends.
Oxehealth
Seed Round in 2012
Oxehealth Ltd. is a technology company based in Oxford, United Kingdom, that specializes in non-contact vital signs monitoring solutions. Founded in 2012, the company has developed the Oxecam software, which enables the measurement of heart rate, respiratory rate, and blood oxygenation using a digital video camera. This innovative system is particularly beneficial in healthcare settings, including mental health facilities and care homes, where staff may not always be present to monitor patients. Oxehealth's technology provides alerts for potentially risky activities and offers objective data for care planning, enhancing the ability of clinicians and caregivers to support vulnerable individuals. By employing advanced algorithms that utilize deep learning and computer vision, Oxehealth aims to improve patient monitoring and management while allowing staff more time for direct care. The company has achieved world-first certification for its software as a medical device, marking a significant advancement in remote patient monitoring.
Brainomix
Venture Round in 2012
Brainomix Limited, established in 2010 as a spin-out from the University of Oxford, develops advanced imaging biomarkers and software solutions aimed at enhancing clinical decision-making for neurological and cerebrovascular disorders. The company's flagship product, e-Stroke, employs state-of-the-art artificial intelligence algorithms to automate the interpretation of brain scans, specifically for acute ischemic stroke patients. This tool assists physicians in identifying and quantifying early stroke damage, thereby facilitating timely and informed treatment decisions. In addition to e-Stroke, Brainomix offers other software products such as e-ASPECTS, which automates the Alberta Stroke Program Early CT Score, and e-CTA, which standardizes the assessment of large vessel occlusion locations. These innovative solutions address the critical need for rapid and consistent evaluations of brain CT scans, ultimately optimizing patient outcomes and ensuring that stroke patients receive appropriate care in a timely manner. The company is headquartered in Oxford, United Kingdom.
Onfido
Convertible Note in 2012
Onfido Limited, established in 2010 and headquartered in London, specializes in digital identity verification. The company offers a SaaS solution that uses AI-based technology to verify government-issued IDs and match them with facial biometrics, ensuring users' identities are genuine. Onfido's platform is employed in various sectors, including financial services, marketplaces, gaming, and e-commerce, for applications such as KYC, user onboarding, and fraud detection. The company operates globally with offices in major cities like San Francisco, New York, Lisbon, Paris, New Delhi, and Singapore.
MeVitae
Venture Round in 2012
MeVitae operates an online recruitment platform designed to enhance diversity and inclusivity in hiring processes for organizations. The platform utilizes data-driven technology to assist businesses in attracting, screening, and retaining top talent while ensuring a fair approach to building diverse and productive teams. By integrating seamlessly with existing applicant tracking systems (ATS) and customer relationship management (CRM) tools, MeVitae allows companies to maintain their current processes without disruption. The solution emphasizes the importance of personalized hiring that aligns with a company's culture, all while eliminating algorithmic and neurological biases. This enables clients to achieve a more transparent and efficient automated talent acquisition process.
WhatsOnCampus
Venture Round in 2012
WhatsOnCampus connects students to activities happening on and around their campus.
Active Inspiration Technologies
Venture Round in 2012
Award winning digital health platform called "Fuell" with a goal of getting Employees to achieve weekly health goals. Data Collection from wearables Engagement through self service and sponsored challenges Loyalty and Monetisation through tokens Low cost monthly subscription with data driven outcomes for Employers, Brands and Organisations.
Oxford Imaging Detectors
Seed Round in 2011
Oxford Imaging Detectors develops high performance scientific imaging detectors capable of studying structures and processes at the atomic level.
Esplorio
Venture Round in 2011
Esplorio, established in 2012 and headquartered in Oxford, UK, operates an online platform that enables users to document and share their travel experiences. The company's core product is a digital travel diary, which aggregates social media content and travel data to create personalized, shareable travel journals. Users can relive and recount their adventures through this platform, which is accessible via an iOS app.
OxGeos
Venture Round in 2011
Oxford Geo-Social Technologies – OXGEOS™ was founded in March 2012, in Oxford, United Kingdom. OXGEOS has a core team of Oxford Graduates who are motivated by a world of possibilities for geo-social technology.OXGEOS provides world class platforms for social games, social communities and geo-social advertising technologies.
Pilio
Venture Round in 2011
Pilio Ltd is a London-based company established in 2011 that specializes in energy management software designed to support estate energy management solutions. The company leverages advanced weather analysis algorithms and energy efficiency benchmarking to accurately calculate and track energy savings for its clients. Pilio provides intuitive dashboards and reports developed by energy experts, allowing businesses to monitor their energy consumption and savings effectively. Additionally, Pilio offers consultancy services that help organizations implement strategies aimed at achieving net-zero emissions and fostering a nature-positive approach. By combining software tools with expert guidance, Pilio equips clients to actively engage in the green economy while enhancing their operational resilience.
Colwiz
Venture Round in 2011
colwiz (collective wizdom) is a free research management, collaboration and productivity platform for individual researchers, groups, departments and organizations. Utilizing web, desktop (Windows, Mac , Linux) and mobile applications synced in real time, the platform manages the entire research lifecycle from an initial idea, through a complex collaboration, to publication of the results. colwiz The company was founded by leading researchers from the University of Oxford.
IXO Therapeutics
Seed Round in 2010
IXO Therapeutics Ltd. is a biotechnology company formed to research and develop novel medicines from natural sources for the treatment of immune-mediated and inflammatory diseases.
Kepler Energy
Seed Round in 2010
Kepler Energy Limited is a UK-based development stage company founded in 2010, focused on the development and manufacturing of innovative tidal turbines designed to harness tidal energy. The company holds an exclusive license for a patented second-generation tidal turbine, originally developed by academics at the University of Oxford. Kepler's turbines are distinct in their larger, scalable design and capability to operate effectively in low tidal stream velocities, which are common in coastal waters worldwide. This technology allows for the construction of tidal fences, optimizing energy production and providing incremental revenue during the construction phase. Kepler Energy aims to address gaps in the tidal energy market by offering a cost-effective and powerful solution for sustainable energy generation, positioning itself as a leader in this emerging sector without direct economic competitors in specific resource areas.
Navetas Energy Management
Series B in 2010
Navetas Energy Management Ltd. is an energy management company based in Woodbridge, United Kingdom, founded in 2008. It specializes in providing cloud-based energy monitoring and smart data analytics solutions primarily for residential customers. The company's primary offering is the Loop connected energy platform, which enables users to monitor their electricity and gas consumption through real-time analytics accessible on various devices. The platform includes the Loop Electricity Starter Kit, which features a sensor and Internet gateway, and the Loop Gas meter for monitoring gas usage. Additionally, Navetas provides a subscription service that allows customers to receive automated tariff advice, helping them compare and manage their energy costs effectively. The company also offers a range of services in energy measurement, procurement, and conservation across industrial and commercial sectors, including the Navetas Zeo Smart Hub for comprehensive meter management. Navetas Energy Management Ltd. previously operated under the name Navetas New Co., Ltd. before rebranding in September 2008 and is currently undergoing reorganization.
Oxford Immunotec
Series D in 2010
Oxford Immunotec is a diagnostics company specializing in the development and commercialization of proprietary tests for immunology and infectious diseases. Headquartered in the UK, with operations in the US, the company's core technology, T-SPOT, measures specific T cell responses to inform diagnosis, prognosis, and monitoring of patients with immune-regulated conditions. Its flagship product, T-SPOT.TB, detects active and latent tuberculosis infection, while T-SPOT.CMV monitors cytomegalovirus in transplant recipients. Oxford Immunotec serves independent laboratories, hospital systems, and public and private institutions worldwide.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.